HALO Halozyme Therapeutics Inc

Price (delayed)

$45.25

Market cap

$6.12B

P/E Ratio

47.63

Dividend/share

N/A

EPS

$0.95

Enterprise value

$6.37B

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's equity has surged by 65% YoY and by 53% QoQ
HALO's gross profit is up by 49% YoY and by 35% QoQ
Halozyme Therapeutics's quick ratio has plunged by 93% from the previous quarter and by 80% YoY

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
135.28M
Market cap
$6.12B
Enterprise value
$6.37B
Valuations
Price to earnings (P/E)
47.63
Price to book (P/B)
40.5
Price to sales (P/S)
23.03
EV/EBIT
42.56
EV/EBITDA
41.65
EV/Sales
23.81
Earnings
Revenue
$267.59M
EBIT
$149.68M
EBITDA
$152.96M
Free cash flow
$54.03M
Per share
EPS
$0.95
Free cash flow per share
$0.4
Book value per share
$1.12
Revenue per share
$1.96
TBVPS
$4.26
Balance sheet
Total assets
$579.92M
Total liabilities
$428.88M
Debt
$397.23M
Equity
$151.05M
Working capital
$133.38M
Liquidity
Debt to equity
2.63
Current ratio
1.32
Quick ratio
1.11
Net debt/EBITDA
1.63
Margins
EBITDA margin
57.2%
Gross margin
83.8%
Net margin
48.2%
Operating margin
53.9%
Efficiency
Return on assets
24.3%
Return on equity
124.8%
Return on invested capital
22%
Return on capital employed
94.4%
Return on sales
55.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
-4.35%
1 week
-8.92%
1 month
-6.99%
1 year
113.75%
YTD
5.95%
QTD
5.95%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$267.59M
Gross profit
$224.23M
Operating income
$144.26M
Net income
$129.09M
Gross margin
83.8%
Net margin
48.2%
HALO's gross profit is up by 49% YoY and by 35% QoQ
The company's revenue rose by 37% YoY and by 34% QoQ
Halozyme Therapeutics's gross margin has increased by 9% YoY

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
P/E
47.63
P/B
40.5
P/S
23.03
EV/EBIT
42.56
EV/EBITDA
41.65
EV/Sales
23.81
The company's equity has surged by 65% YoY and by 53% QoQ
HALO's price to book (P/B) is 44% higher than its 5-year quarterly average of 28.1 and 7% higher than its last 4 quarters average of 38.0
The price to sales (P/S) is 86% higher than the 5-year quarterly average of 12.4 and 23% higher than the last 4 quarters average of 18.7
The company's revenue rose by 37% YoY and by 34% QoQ

Efficiency

How efficient is Halozyme Therapeutics business performance
HALO's return on sales has surged by 174% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 35% higher than its total liabilities
The company's current ratio has shrunk by 93% QoQ and by 79% YoY
Halozyme Therapeutics's quick ratio has plunged by 93% from the previous quarter and by 80% YoY
The debt is 163% more than the equity
The company's equity has surged by 65% YoY and by 53% QoQ
Halozyme Therapeutics's debt to equity has decreased by 40% YoY and by 34% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.